NCT04334551 is a Phase 4 clinical trial of Doravirine in HIV Infections, sponsored by Clinique du Quartier Latin.

Who is sponsoring NCT04334551?

NCT04334551 is sponsored by Clinique du Quartier Latin.

What drugs are being tested in NCT04334551?

Interventions in NCT04334551: Doravirine.

What condition does NCT04334551 study?

NCT04334551 studies HIV Infections.

Is NCT04334551 still recruiting?

NCT04334551 is currently status unknown. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT04334551

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

Status unknown Phase 4 Last updated 29 January 2021

What this trial tests

Phase 4 trial testing Doravirine in HIV Infections in 40 participants. Status unknown.

Timeline

23 June 2020

Primary endpoint
14 July 2022

1 October 2022

Quick facts

Lead sponsor	Clinique du Quartier Latin
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	23 June 2020
Primary completion	14 July 2022
Estimated completion	1 October 2022
Sites	3 locations across Martinique, Canada

Drugs / interventions tested

Doravirine (DORAVIRINE) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Clinique du Quartier Latin

Who can join

Adults 18 to 90, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot, open, prospective, non-randomized study to evaluate the safety and efficacy of switches from etravirine to doravirine, in experienced patients with multiple class resistance including NNRTI resistance. The other ARV medication (protease inhibitor, entry inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and NNRTI, will not be changed. The study will be performed only on two sites

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Doravirine

Trials testing the same drug.

NCT05761509 — "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" · completed
NCT04892654 — Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch · Phase 3 · recruiting
NCT04900974 — Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women · Phase 1 · completed
NCT04689737 — Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD) · Phase 4 · completed
NCT04375800 — Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-0 · Phase 2 · recruiting

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04334551 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinique du Quartier Latin
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04334551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing